| Orginal Article |
|
|
|
|
| Current Status of Research on Coronavirus |
| Clarivate Analytics |
|
|
|
Abstract The outbreak of COVID-2019 has attracted the attention of the international community. This comprehensive review summarizes the research progress of the diagnosis, prevention and treatment of coronaviruses including SARS-CoV and MERS-CoV, which were extracted and compiled from the Cortellis report DISEASE BRIEFING: CORONAVIRUSES (published on January 30th, 2020), in order to provide reference for the scientific research of current epidemic situation.
|
|
Published: 27 March 2020
|
|
|
| [1] |
Huang C, Wang Y, Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China. The Lancet, 2020.
|
|
|
| [2] |
Hui DS, I Azhar E, Madani TA , et al. The continuing COVID-19 epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan,China. Int J Infect Dis, 2020,91:264-266.
|
|
|
| [3] |
Zhu N, Zhang D, Wang W , et al. A Novel Coronavirus from Patients with Pneumonia in China,2019. New England Journal of Medicine, 2020.
|
|
|
| [4] |
Perlman S . Another Decade,Another Coronavirus. New England Journal of Medicine, 2020.
|
|
|
| [5] |
Cleri DJ, Ricketti AJ, Vernaleo JR . Severe Acute Respiratory Syndrome (SARS). Infectious Disease Clinics of North America, 2010,24(1):175-+.
|
|
|
| [6] |
Paules CI, Marston HD, Fauci AS . Coronavirus Infections-More Than Just the Common Cold. JAMA, 2020.
|
|
|
| [7] |
Chan PKS, Chan MCW . Tracing the SARS-coronavirus. Journal of Thoracic Disease, 2013,5:S118-S121.
|
|
|
| [8] |
Berry M, Gamieldien J, Fielding BC . Identification of New Respiratory Viruses in the New Millennium. Viruses-Basel, 2015,7(3):996-1019.
|
|
|
| [9] |
Arabi YM, Balkhy HH, Hayden FG , et al. Middle East Respiratory Syndrome. New England Journal of Medicine, 2017,376(6):584-594.
|
|
|
| [10] |
Skariyachan S, Challapilli SB, Packirisamy S , et al. Recent Aspects on the Pathogenesis Mechanism,Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections. Frontiers in Microbiology, 2019,10.
|
|
|
| [11] |
Zumla A, Chan JFW, Azhar EI , et al. Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery, 2016,15(5):327-347.
|
|
|
| [12] |
Zumla A, Hui DS, Perlman S . Middle East respiratory syndrome. Lancet, 2015,386(9997):995-1007.
|
|
|
| [13] |
World Health Organization. A research and development blueprint for action to prevent epidemics[R]. Geneva:WHO, 2018.
|
|
|
| [14] |
World Health Organization. Emergencies: Novel coronavirus 2019[R]. Geneva:WHO, 2020.
|
|
|
| [15] |
World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan,China[R]. Geneva:WHO, 2020.
|
|
|
| [16] |
Chan JF-W, Yao Y, Yeung M-L , et al. Treatment With Lopinavir/Ritonavir or Interferon-beta 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. Journal of Infectious Diseases, 2015,212(12):1904-1913.
|
|
|
| [17] |
Song Z, Xu Y, Bao L , et al. From SARS to MERS,Thrusting Coronaviruses into the Spotlight. Viruses-Basel, 2019,11(1).
|
|
|
| [18] |
Tseng Y-T, Wang S-M, Huang K-J , et al. Self-assembly of Severe Acute Respiratory Syndrome Coronavirus Membrane Protein. Journal of Biological Chemistry, 2010,285(17):12862-12872.
|
|
|
| [19] |
Kilianski A, Baker SC . Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. 2014,101(1):105-112.
|
|
|
| [20] |
Raj VS, Osterhaus ADME, Fouchier RAM , et al. MERS: emergence of a novel human coronavirus. Current Opinion in Virology, 2014,5:58-62.
|
|
|
| [21] |
Gralinski LE, Baric RS . Molecular pathology of emerging coronavirus infections. Journal of Pathology, 2015,235(2):185-195.
|
|
|
| [22] |
To KKW, Hung IFN, Chan JFW , et al. From SARS coronavirus to novel animal and human coronaviruses. Journal of Thoracic Disease, 2013,5:S103-S108.
|
|
|
| [23] |
Cabeca TK, Granato C, Bellei N . Epidemiological and clinical features of human coronavirus infections among different subsets of patients. Influenza and Other Respiratory Viruses, 2013,7(6):1040-1047.
|
|
|
| [24] |
Hu Q, Lu R, Peng K , et al. Prevalence and Genetic Diversity Analysis of Human Coronavirus OC43 among Adult Patients with Acute Respiratory Infections in Beijing,2012. Plos One, 2014,9(7).
|
|
|
| [25] |
Reina J, Lopez-Causape C, Rojo-Molinero E , et al. Clinico-epidemiological characteristics of acute respiratory infections caused by coronavirus OC43,NL63 and 229E. Revista Clinica Espanola, 2014,214(9):499-504.
|
|
|
| [26] |
Zhou P, Fan H, Lan T , et al. Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. Nature, 2018,556(7700):255-+.
|
|
|
| [27] |
Centers for Disease Control and Prevention. First travel-related case of 2019 novel coronavirus detected in United States CDC press release[R]. Atlanta:CDC, 2020.
|
|
|
| [28] |
Anderson LJ, Tong S . Update on SARS research and other possibly zoonotic coronaviruses. International Journal of Antimicrobial Agents, 2010,36:S21-S25.
|
|
|
| [29] |
Heymann DL, Mackenzie JS, Peiris M . SARS legacy: outbreak reporting is expected and respected. Lancet, 2013,381(9869):779-781.
|
|
|
| [30] |
Hui DSC . An overview on Severe Acute Respiratory Syndrome (SARS). Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro,IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio,Università di Napoli, Secondo ateneo, 2005,63:149-157.
|
|
|
| [31] |
European Centre for Disease Prevention and Control. Annual epidemiological report 2013: Reporting on 2011[R] Stockholm: ECDC, 2013.
|
|
|
| [32] |
Zhang Y, Yu Y-S, Tang Z-H , et al. 10th anniversary of SARS: China is better prepared for the H7N9 avian influenza outbreak. Journal of Infection in Developing Countries, 2013,7(10):761-762.
|
|
|
| [33] |
Cheng VCC, Chan JFW, To KKW , et al. Clinical management and infection control of SARS: Lessons learned. Antiviral Research, 2013,100(2):407-419.
|
|
|
| [34] |
Al-Tawfiq JA, Memish ZA . Middle East respiratory syndrome coronavirus: epidemiology and disease control measures. Infection and Drug Resistance, 2014,7:281-287.
|
|
|
| [35] |
Gerberding JL . Faster ... but fast enough? Responding to the epidemic of severe acute respiratory syndrome. New England Journal of Medicine, 2003,348(20):2030-2031.
|
|
|
| [36] |
Falsey AR, Walsh EE . Novel coronavirus and severe acute respiratory syndrome. Lancet, 2003,361(9366):1312-1313.
|
|
|
| [37] |
Fouchier RAM, Kuiken T, Schutten M , et al. Aetiology - Koch’s postulates fulfilled for SARS virus. Nature, 2003,423(6937):240-240.
|
|
|
| [38] |
Kuiken T, Fouchier RAM, Schutten M , et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, 2003,362(9380):263-270.
|
|
|
| [39] |
Goldsmith CS, Tatti KM, Ksiazek TG , et al. Ultrastructural characterization of SARS coronavirus. Emerging Infectious Diseases, 2004,10(2):320-326.
|
|
|
| [40] |
Du L, He Y, Zhou Y , et al. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nature Reviews Microbiology, 2009,7(3):226-236.
|
|
|
| [41] |
Ruan YJ, Wei CL, Ee LA , et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet, 2003,361(9371):1779-1785.
|
|
|
| [42] |
Rota PA, Oberste MS, Monroe SS , et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003,300(5624):1394-1399.
|
|
|
| [43] |
Kuba K, Imai Y, Ohto-Nakanishi T , et al. Trilogy of ACE2: A peptidase in the renin-angiotensin system,a SARS receptor,and a partner for amino acid transporters. Pharmacology & Therapeutics, 2010,128(1):119-128.
|
|
|
| [44] |
Vicenzi E, Canducci F, Pinna D , et al. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerging Infectious Diseases, 2004,10(3):413-418.
|
|
|
| [45] |
Simmons G, Reeves JD, Rennekamp AJ , et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proceedings of the National Academy of Sciences of the United States of America, 2004,101(12):4240-4245.
|
|
|
| [46] |
Gosert R, Kanjanahaluethai A, Egger D , et al. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. Journal of Virology, 2002,76(8):3697-3708.
|
|
|
| [47] |
Marra MA, Jones SJM, Astell CR , et al. The genome sequence of the SARS-associated coronavirus. Science, 2003,300(5624):1399-1404.
|
|
|
| [48] |
NCBI Sequence Viewer:SARS-CoV.
|
|
|
| [49] |
Holmes KV, Enjuanes L . The SARS coronavirus: A postgenomic era. Science, 2003,300(5624):1377-1378.
|
|
|
| [50] |
Perlman S, Netland J . Coronaviruses post-SARS: update on replication and pathogenesis. Nature Reviews Microbiology, 2009,7(6):439-450.
|
|
|
| [51] |
Abdel-Moneim AS . Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations. Archives of Virology, 2014,159(7):1575-1584.
|
|
|
| [52] |
Rest JS, Mindell DP . SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting. Infection Genetics and Evolution, 2003,3(3):219-225.
|
|
|
| [53] |
Enserink M . Infectious diseases - Clues to the animal origins of SARS. Science, 2003,300(5624):1351-1351.
|
|
|
| [54] |
Hui DSC, Chan PKS . Severe Acute Respiratory Syndrome and Coronavirus. Infectious Disease Clinics of North America, 2010,24(3):619-+.
|
|
|
| [55] |
Wang L-F, Shi Z, Zhang S , et al. Review of bats and SARS. Emerging Infectious Diseases, 2006,12(12):1834-1840.
|
|
|
| [56] |
Wong SSY, Yuen K-Y . The management of coronavirus infections with particular reference to SARS. Journal of Antimicrobial Chemotherapy, 2008,62(3):437-441.
|
|
|
| [57] |
Drosten C, Gunther S, Preiser W , et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England Journal of Medicine, 2003,348(20):1967-1976.
|
|
|
| [58] |
Arita I, Kojima K, Nakane M . Transmission of severe acute respiratory syndrome. Emerging Infectious Diseases, 2003,9(9):1183-1184.
|
|
|
| [59] |
Goh DLM, Lee BW, Chia KS , et al. Secondary household transmission of SARS,Singapore. Emerging Infectious Diseases, 2004,10(2):232-234.
|
|
|
| [60] |
Lau JTF, Lau M, Kim JH , et al. Probable secondary infections in households of SARS patients in Hong Kong. Emerging Infectious Diseases, 2004,10(2):235-243.
|
|
|
| [61] |
Loeb M, McGeer A, Henry B , et al. SARS among critical care nurses,Toronto. Emerging Infectious Diseases, 2004,10(2):251-255.
|
|
|
| [62] |
Chen W-Q, Ling W-H, Lu C-Y , et al. Which preventive measures might protect health care workers from SARS? Bmc Public Health, 2009,9.
|
|
|
| [63] |
Seto WH, Tsang D, Yung RWH , et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet, 2003,361(9368):1519-1520.
|
|
|
| [64] |
McDonald LC, Simor AE, Su IJ , et al. SARS in healthcare facilities,Toronto and Taiwan. Emerging Infectious Diseases, 2004,10(5):777-781.
|
|
|
| [65] |
Zeng G, Xie S-Y, Li Q , et al. Infectivity of Severe Acute Respiratory Syndrome during Its Incubation Period. Biomedical and Environmental Sciences, 2009,22(6):502-510.
|
|
|
| [66] |
Braden CR, Dowell SF, Jernigan DB , et al. Progress in Global Surveillance and Response Capacity 10 Years after Severe Acute Respiratory Syndrome. Emerging Infectious Diseases, 2013,19(6):864-869.
|
|
|
| [67] |
Gopalakrishna G, Choo P, Leo YS , et al. SARS transmission and hospital containment. Emerging Infectious Diseases, 2004,10(3):395-400.
|
|
|
| [68] |
Nicholls JM, Poon LLM, Lee KC , et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet, 2003,361(9371):1773-1778.
|
|
|
| [69] |
Zhang D-m, Lu J-h, Zhong N-s . Pathogenesis of severe acute respiratory syndrome. Chinese Medical Journal, 2008,121(17):1722-1731.
|
|
|
| [70] |
Lau KK, Yu WC, Chu CM , et al. Possible central nervous system infection by SARS coronavirus. Emerging Infectious Diseases, 2004,10(2):342-344.
|
|
|
| [71] |
Peiris JSM, Chu CM, Cheng VCC , et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet, 2003,361(9371):1767-1772.
|
|
|
| [72] |
Poutanen SM, Low DE, Henry B , et al. Identification of severe acute respiratory syndrome in Canada. New England Journal of Medicine, 2003,348(20):1995-2005.
|
|
|
| [73] |
Frieman M, Baric R . Mechanisms of Severe Acute Respiratory Syndrome Pathogenesis and Innate Immunomodulation. Microbiology and Molecular Biology Reviews, 2008,72(4):672-+.
|
|
|
| [74] |
Schaefer A, Baric RS, Ferris MT . Systems approaches to coronavirus pathogenesis. Current Opinion in Virology, 2014,6:61-69.
|
|
|
| [75] |
Yang JK, Feng Y, Yuan MY , et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Medicine, 2006,23(6):623-628.
|
|
|
| [76] |
Liang WN, Zhu ZH, Guo JY , et al. Severe acute respiratory syndrome,Beijing,2003. Emerging Infectious Diseases, 2004,10(1):25-31.
|
|
|
| [77] |
Tansey CM, Louie M, Loeb M , et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Archives of Internal Medicine, 2007,167(12):1312-1320.
|
|
|
| [78] |
Moldofsky H, Patcai J . Chronic widespread musculoskeletal pain,fatigue,depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. Bmc Neurology, 2011,11.
|
|
|
| [79] |
Lam MH-B, Wing Y-K, Yu MW-M , et al. Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory Syndrome Survivors Long-term Follow-up. Archives of Internal Medicine, 2009,169(22):2142-2147.
|
|
|
| [80] |
Ngai JC, Ko FW, Ng SS , et al. The long-term impact of severe acute respiratory syndrome on pulmonary function,exercise capacity and health status. Respirology, 2010,15(3):543-550.
|
|
|
| [81] |
World Health Organization. Summary table of SARS cases by country, 1 November 2002 - 7 August 2003 [R]. Geneva:WHO, 2003.
|
|
|
| [82] |
Lau EHY, Hsiung CA, Cowling BJ , et al. A comparative epidemiologic analysis of SARS in Hong Kong,Beijing and Taiwan. Bmc Infectious Diseases, 2010,10.
|
|
|
| [83] |
Kondro W . Canadians still stung by WHO’s SARS travel advisory. Lancet, 2003,361(9369):1624-1624.
|
|
|
| [84] |
Beutels P, Jia N, Zhou Q-Y , et al. The economic impact of SARS in Beijing,China. Tropical Medicine & International Health, 2009,14:85-91.
|
|
|
| [85] |
Milne-Price S, Miazgowicz KL, Munster VJ . The emergence of the Middle East Respiratory Syndrome coronavirus. Pathogens and Disease, 2014,71(2):119-134.
|
|
|
| [86] |
Cho H, Excler J-L, Kim JH , et al. Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges. Human Vaccines & Immunotherapeutics, 2018,14(2):304-313.
|
|
|
| [87] |
Perlman S, Zhao J . Human Coronavirus EMC Is Not the Same as Severe Acute Respiratory Syndrome Coronavirus. Mbio, 2013,4(1).
|
|
|
| [88] |
Raj VS, Mou H, Smits SL , et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 2013,495(7440):251-254.
|
|
|
| [89] |
Li F, Du L . MERS Coronavirus: An Emerging Zoonotic Virus. Viruses-Basel, 2019,11(7).
|
|
|
| [90] |
Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected - Interim guidance (World Health Organization, 2019)
|
|
|
| [91] |
World Health Organization. WHO Global Alert and Response (GAR): Coronavirus infections[R/OL]. https://www.who.int/emergencies/mers-cov/en/
|
|
|
| [92] |
Banik GR, Khandaker G, Rashid H . Middle East Respiratory Syndrome Coronavirus “MERS-CoV”: Current Knowledge Gaps. Paediatric Respiratory Reviews, 2015,16(3):197-202.
|
|
|
| [93] |
Adney DR, van Doremalen N, Brown VR , et al. Replication and Shedding of MERS-CoV in Upper Respiratory Tract of Inoculated Dromedary Camels. Emerging Infectious Diseases, 2014,20(12):1999-2005.
|
|
|
| [94] |
Widagdo W, Ayudhya SSN, Hundie GB , et al. Host Determinants of MERS-CoV Transmission and Pathogenesis. Viruses-Basel, 2019,11(3).
|
|
|
| [95] |
Bin SY, Heo JY, Song M-S , et al. Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea. Clinical Infectious Diseases, 2016,62(6):755-760.
|
|
|
| [96] |
Al-Tawfiq JA, Zumla A, Memish ZA . Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers. Current Opinion in Infectious Diseases, 2014,27(5):411-417.
|
|
|
| [97] |
Chafekar A, Fielding BC . MERS-CoV: Understanding the Latest Human Coronavirus Threat. Viruses-Basel, 2018,10(2).
|
|
|
| [98] |
Cauchemez S, Fraser C, Van Kerkhove MD , et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic,surveillance biases,and transmissibility. Lancet Infectious Diseases, 2014,14(1):50-56.
|
|
|
| [99] |
World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)[R/OL]. https://www.who.int/emergencies/mers-cov/en/.
|
|
|
| [100] |
Assiri A, McGeer A, Perl TM , et al. Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus. New England Journal of Medicine, 2013,369(5):407-416.
|
|
|
| [101] |
Mueller MA, Meyer B, Corman VM , et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide,cross-sectional,serological study. Lancet Infectious Diseases, 2015,15(5):559-564.
|
|
|
| [102] |
O’Hagan JJ, Carias C, Rudd JM , et al. Estimation of Severe Middle East Res or t ry Syndrome Cases in the Middle East,2012-2016. Emerging Infectious Diseases, 2016,22(10):1797-1799.
|
|
|
| [103] |
Breban R, Riou J, Fontanet A . Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet, 2013,382(9893):694-699.
|
|
|
| [104] |
Alexander E G, Susan C B, Ralph S B , et al. Severe acute respiratory syndrome-related coronavirus - The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv [Preprint], February 07, 2020 [cited 2020 Feb 13] https://doi.org/10.1101/2020.02.07.937862.
|
|
|
| [105] |
Munster VJ, Koopmans M, van Doremalen N , et al. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. New England Journal of Medicine, 2020.
|
|
|
| [106] |
World Health Organization. Coronavirus disease (COVID-2019) situation reports [R/OL]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
|
|
|
| [107] |
Bhatnagar PK, Das D, Suresh MR . Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). Journal of Pharmacy and Pharmaceutical Sciences, 2008,11(2):1-13.
|
|
|
| [108] |
Jernigan JA, Low DE, Helfand RF . Combining clinical and epidemiologic features for early recognition of SARS. Emerging Infectious Diseases, 2004,10(2):327-333.
|
|
|
| [109] |
Chan KH, Poon L, Cheng VCC , et al. Detection of SARS coronavirus in patients with suspected SARS. Emerging Infectious Diseases, 2004,10(2):294-299.
|
|
|
| [110] |
Peiris J, Poon L . Detection of SARS coronavirus in humans and animals by conventional and quantitative (real time) reverse transcription polymerase chain reactions. Methods Mol Biol, 2008,454:61-72.
|
|
|
| [111] |
Emery SL, Erdman DD, Bowen MD , et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerging Infectious Diseases, 2004,10(2):311-316.
|
|
|
| [112] |
Bhadra S, Jiang YS, Kumar MR , et al. Real-Time Sequence-Validated Loop-Mediated Isothermal Amplification Assays for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Plos One, 2015,10(4).
|
|
|
| [113] |
Jefferson T, Del Mar C, Dooley L , et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: A Cochrane review. Health technology assessment (Winchester, England), 2010,14:347-476.
|
|
|
| [114] |
Hsieh Y-H, King C-C, Chen CWS , et al. Impact of quarantine on the 2003 SARS outbreak: A retrospective modeling study. Journal of Theoretical Biology, 2007,244(4):729-736.
|
|
|
| [115] |
Embarek PKB, Kerkhove MDV . Middle East respiratory syndrome coronavirus (MERS-CoV): current situation 3 years after the virus was first identified. Releve epidemiologique hebdomadaire / Section d’hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, 2015,90(20):245-250.
|
|
|
| [116] |
Wirblich C, Coleman CM, Kurup D , et al. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. Journal of Virology, 2017,91(2).
|
|
|
| [117] |
Song Z, Xu Y, Bao L , et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses-Basel, 2019,11(1).
|
|
|
| [118] |
Ma C, Li Y, Wang L , et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine, 2014,32(18):2100-2108.
|
|
|
| [119] |
Zhang N, Tang J, Lu L , et al. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Research, 2015,202:151-159.
|
|
|
| [120] |
Schindewolf C, Menachery VD . Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Viruses, 2019,11(1).
|
|
|
| [121] |
Gao WT, Tamin A, Soloff A , et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet, 2003,362(9399):1895-1896.
|
|
|
| [122] |
Enserink M . Infectious diseases - WHO wants 21st-century reporting regs. Science, 2003,300(5620):717-718.
|
|
|
| [123] |
Arabi YM, Fowler R, Bright RA , et al. Knowledge gaps in therapeutic and non-therapeutic research on the Middle East respiratory syndrome. Lancet Respiratory Medicine, 2016,4(2):93-94.
|
|
|
| [124] |
Momattin H, Al-Ali AY, Al-Tawfiq JA . A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel Medicine and Infectious Disease, 2019,30:9-18.
|
|
|
| [125] |
Lee N, Hui D, Wu A , et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine, 2003,348(20):1986-1994.
|
|
|
| [126] |
So LKY, Lau ACW, Yam LYC , et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet, 2003,361(9369):1615-1617.
|
|
|
| [127] |
Tai DYH . Pharmacologic treatment of SARS: Current knowledge and recommendations. Annals Academy of Medicine Singapore, 2007,36(6):438-443.
|
|
|
| [128] |
Stockman LJ, Bellamy R, Garner P . SARS: Systematic review of treatment effects. Plos Medicine, 2006,3(9):1525-1531.
|
|
|
| [129] |
Dyall J, Coleman CM, Hart BJ , et al. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection. Antimicrobial Agents and Chemotherapy, 2014,58(8):4885-4893.
|
|
|
| [130] |
de Wilde AH, Jochmans D, Posthuma CC , et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture. Antimicrobial Agents and Chemotherapy, 2014,58(8):4875-4884.
|
|
|
| [131] |
Wei-dong JIA, Xi-long D, Xiao-ping T , et al. Dose of glucocorticosteroids in the treatment of severe acute respiratory syndrome. Journal of Southern Medical University, 2009,29(11):2284-2287.
|
|
|
| [132] |
Falzarano D, Wit E, Rasmussen AL , et al. Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nature Medicine, 2013,19(10):1313.
|
|
|
| [133] |
Omrani AS, Saad MM, Baig K , et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infectious Diseases, 2014,14(11):1090-1095.
|
|
|
| [134] |
Pfefferle S, Schöpf J, Kögl M , et al. The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors. PLoS pathogens, 2011,7:e1002331.
|
|
|
| [135] |
Zhou Y, Vedantham P, Lu K , et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research, 2015,116:76-84.
|
|
|
| [136] |
Millet JK, Whittaker GR . Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Research, 2015,202:120-134.
|
|
|
| [137] |
Arabi YM, Alothman A, Balkhy HH , et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta 1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 2018,19.
|
|
|
| [138] |
Adedeji AO, Singh K, Kassim A , et al. Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses. Antimicrobial Agents and Chemotherapy, 2014,58(8):4894-4898.
|
|
|
| [139] |
Hensley LE, Fritz EA, Jahrling PB , et al. Interferon-beta 1a and SARS coronavirus replication. Emerging Infectious Diseases, 2004,10(2):317-319.
|
|
|
| [140] |
Cinatl J, Morgenstern B, Bauer G , et al. Treatment of SARS with human interferons. Lancet, 2003,362(9380):293-294.
|
|
|
| [141] |
Loutfy MR, Blatt LM, Siminovitch KA , et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome - A preliminary study. Jama-Journal of the American Medical Association, 2003,290(24):3222-3228.
|
|
|
| [142] |
Tan ELC, Ooi EE, Lin CY , et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases, 2004,10(4):581-586.
|
|
|
| [143] |
Goldstein AL, Goldsten AL . From lab to bedside: emerging clinical applications of thymosin alpha(1). Expert Opinion on Biological Therapy, 2009,9(5):593-608.
|
|
|
| [144] |
Peiris JSM, Lai ST, Poon LLM , et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 2003,361(9366):1319-1325.
|
|
|
| [145] |
Normile D . Infectious diseases - Battling SARS on the frontlines. Science, 2003,300(5620):714-715.
|
|
|
| [146] |
Mazzulli T, Farcas GA, Poutanen SM , et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerging Infectious Diseases, 2004,10(1):20-24.
|
|
|
| [147] |
Mair-Jenkins J, Saavedra-Campos M, Baillie JK , et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. Journal of Infectious Diseases, 2015,211(1):80-90.
|
|
|
| [148] |
Arabi YM, Hajeer AH, Luke T , et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerging Infectious Diseases, 2016,22(9):1554-1561.
|
|
|
| [149] |
Jin Y, Lei C, Hu D , et al. Human monoclonal antibodies as candidate therapeutics against emerging viruses. Frontiers of Medicine, 2017,11(4):462-470.
|
|
|
| [150] |
Sui JH, Li WH, Murakami A , et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proceedings of the National Academy of Sciences of the United States of America, 2004,101(8):2536-2541.
|
|
|
| [151] |
Zhu Z, Chakraborti S, He Y , et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2007,104(29):12123-12128.
|
|
|
| [152] |
Ying T, Du L, Ju TW , et al. Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. Journal of Virology, 2014,88(14):7796-7805.
|
|
|
| [153] |
Ohnuma K, Haagmans BL, Hatano R , et al. Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody. Journal of Virology, 2013,87(24):13892-13899.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
